ArticlePloS one2009
Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Aspirin and the chemoprevention of cancers: A mathematical and evolutionary dynamics perspective.Wiley interdisciplinary reviews. Systems biology and medicine · 2020Review
- Article
- A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1Leukemia research · 2019Article
- Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.PloS one · 2019Article
- Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A.Oncology letters · 2019Article
- Effect of aspirin on tumour cell colony formation and evolution.Journal of the Royal Society, Interface · 2017Article
- Article
- The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia.Journal of biomedical research · 2016Article
- Optimized Treatment Schedules for Chronic Myeloid Leukemia.PLoS computational biology · 2016Article
- Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.PLoS computational biology · 2016Article
- Diverse array-designed modes of combination therapies in Fangjiomics.Acta pharmacologica Sinica · 2015Review
- Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy.PLoS computational biology · 2015Article
- A Review of Mathematical Models for Leukemia and Lymphoma.Drug discovery today. Disease models · 2015Article
- Evolution of acquired resistance to anti-cancer therapy.Journal of theoretical biology · 2014Review
- Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Expert review of anticancer therapy · 2013Review
- Cancer: calculated treatment.Nature · 2013Article
- Article
- Article
- Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.Haematologica · 2012Article
- Dynamics of targeted cancer therapy.Trends in molecular medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic myeloid leukemia (CML) is a cancer of the hematopoietic system and has been treated with the drug Imatinib relatively successfully. Drug resistance, acquired by mutations, is an obstacle to success. Two additional drugs are now considered and could be combined with Imatinib to prevent resistance, Dasatinib and Nilotinib. While most mutations conferring resistance to one drug do not confer resistance to the other drugs, there is one mutation (T315I) that induces resistance against all three drugs. Using computational methods, the combination of two drugs is found to increase the probability of treatment success despite this cross-resistance. Combining more than two drugs, however, does not provide further advantages. We also explore possible combination therapies using drugs currently under development. We conclude that among the targeted drugs currently available for the treatment of CML, only the two most effective ones should be used in combination for the prevention of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.